References

Abubakar, I., Zignol, M., Falzon, D., et al. (2013). Drug-resistant tuberculosis: time for visionary political leadership, 13(6):529-539. http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(13)70030-6/fulltext

Agarwal. (2010). M-tuberculosis-on-Lowenstein-Jensen. Wikimedia Commons. https://commons.wikimedia.org/wiki/File:M-tuberculosis-on-Lowenstein-Jensen.jpg

Ahuja, S. D., Ashkin, D., et al. (2012). Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Medicine, 9(8), e1001300. https://doi.org/10.1371/journal.pmed.1001300

Boehme, C. C., Nabeta, P., et al. (2010). Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine, 363(11), 1005–1015. https://doi.org/10.1056/nejmoa0907847

Brazier, B., & McShane, H. (2020). Towards new TB vaccines. Seminars in immunopathology, 42(3), 315–331. https://doi.org/10.1007/s00281-020-00794-0

Cegielski, P., Nunn, P., Kurbatova, E., et al. (2012). Challenges and controversies in defining totally drug-resistant tuberculosis. http://wwwnc.cdc.gov/eid/article/18/11/12-0526_article.htm.

Centers for Disease Control and Prevention (CDC). (2016). Fact Sheets 2016: BCG vaccine. www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm.

Clinical testing guidance for tuberculosis: interferon gamma release assay. (2024, May 9). Centers for Disease Control and Prevention. https://www.cdc.gov/tb/hcp/testing-diagnosis/interferon-gamma-release-assay.html

Centers for Disease Control and Prevention (CDC). (2022). Trends in tuberculosis—United States 2021.https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7112a1-H.pdf.

Filia, A., Ciarrocchi, G., Belfiglio, R., Caferri, M., Bella, A., Piersimoni, C., Cirillo, D., Grilli, G., Mancini, C., & Greco, D. (2011). Tuberculosis in kindergarten and primary School, Italy, 2008–2009. Emerging Infectious Diseases, 17(3), 514–516. https://doi.org/10.3201/eid1703.101440

Fitzgerald, D., & Haas, D. (2012). Mycobacterium tuberculosis. (9th ed.) Elsevier Inc.

Garfein, R. S., Laniado-Laborin, R., Rodwell, T. C., Lozada, R., Deiss, R., Burgos, J. L., Cuevas-Mota, J., Cerecer, P., Moser, K., Volker, M. L., & Strathdee, S. A. (2010). Latent Tuberculosis among Persons at Risk for Infection with HIV, Tijuana, Mexico. Emerging Infectious Diseases, 16(5), 757–763. https://doi.org/10.3201/eid1605.091446

Kokko, U.P. (1963). #12128. Centers for Disease Control and Prevention. https://phil.cdc.gov/Details.aspx?pid=12128

Kubica, George P. (1979). #5789. Centers for Disease Control and Prevention. https://phil.cdc.gov/Details.aspx?pid=5789

Kubica, George P. (1976). #16484. Centers for Disease Control and Prevention. https://phil.cdc.gov/Details.aspx?pid=16484

Lee, S. (2016). Tuberculosis infection and latent tuberculosis. Tuberc Respir Dis (Seoul). 79(4):201-206. doi:10.4046/trd.2016.79.4.201

Lin, S., Probert ,W., et al. (2004). Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons. Journal of clinical microbiology, 42(9), 4204–4208. https://doi.org/10.1128/JCM.42.9.4204-4208.2004

McKinnon, J. (2012). Budget cuts hit TB clinics at the border. California Health Report. https://www.calhealthreport.org/2012/04/02/budget-cuts-hit-tb-clinics-at-the-border/

Migliori, G. B., Ortmann, J., Girardi, E., Besozzi, G., Lange, C., Cirillo, D. M., Ferrarese, M., De Iaco, G., Gori, A., & Raviglione, M. (2007). Extensively drug-resistant tuberculosis, Italy and Germany. Emerging Infectious Diseases, 13(5), 780–782. https://doi.org/10.3201/eid1305.070200

National Library of Medicine (NIH). (n.d.). "Robert Koch". https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101420766-img

New York State Hospital at Ray Brook - Historic Saranac Lake - LocalWiki. (n.d.). LocalWiki. https://localwiki.org/hsl/New_York_State_Hospital_at_Ray_Brook

Parrish, N. M., & Carroll, K. C. (2011). Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings. Journal of clinical microbiology, 49(3), 772–776. https://doi.org/10.1128/JCM.02451-10

Pipeline of vaccines. (2024). TuBerculosis Vaccine Initiative. https://www.tbvi.eu/what-we-do/pipeline-of-vaccines/

Pfyffer, G. (2019). Mycobacterium: General characteristics, laboratory detection, and staining procedures. Manual of Clinical Microbiology. (12th ed.) ASM Press.

Phillips, L. (2013). Infectious disease: TB’s revenge. Nature. http://www.nature.com/news/infectious-disease-tb-s-revenge-1.12115.

Pinon, M., Scolfaro, C., Bignamini, E., Cordola, G., Esposito, I., Milano, R., Mignone, F., Bertaina, C., & Tovo, P. (2010). Two pediatric cases of Multidrug-Resistant tuberculosis treated with linezolid and moxifloxacin. PEDIATRICS, 126(5), e1253–e1256. https://doi.org/10.1542/peds.2009-2172

Reported Tuberculosis in the United States, 2022; Drug-Resistant TB. (2023, November 15). Centers for Disease Control and Prevention. https://www.cdc.gov/tb/statistics/reports/2022/drug_resistant.htm

Richter, E,. Brown-Elliott, B., Wallace Jr., R., et al. (2019). Mycobacterium: Laboratory characteristics of slowly growing mycobacteria. Manual of Clinical Microbiology. (12th ed.). ASM Press.

Russell, D. G., Cardona, P. J., Kim, M. J., Allain, S., & Altare, F. (2009). Foamy macrophages and the progression of the human tuberculosis granuloma. Nature immunology, 10(9), 943–948. https://doi.org/10.1038/ni.1781

Smithwick, R. (1971). #2189. Centers for Disease Control and Prevention. https://phil.cdc.gov/Details.aspx?pid=2189

Smithwick, R. (1975). #14766. Centers for Disease Control and Prevention. https://phil.cdc.gov/Details.aspx?pid=14766

The costly burden of drug resistant TB disease in the U.S. (2021, October 18). Centers for Disease Control and Prevention. https://stacks.cdc.gov/view/cdc/154504

Udwadia, Z. F. (2012). MDR, XDR, TDR tuberculosis: ominous progression. Thorax, 67(4), 286–288. https://doi.org/10.1136/thoraxjnl-2012-201663

Udwadia, Z. F., Amale, R. A., Ajbani, K. K., & Rodrigues, C. (2012). Totally Drug-Resistant Tuberculosis in India. Clinical Infectious Diseases, 54(4), 579–581. https://doi.org/10.1093/cid/cir889

Udwadia Z. F. (2012). Totally drug-resistant tuberculosis in India: who let the djinn out? Respirology (Carlton, Vic.), 17(5), 741–742. https://doi.org/10.1111/j.1440-1843.2012.02192.x

WHO calls for urgent action to end TB. (2018). United Nations Sustainable Development. https://www.un.org/sustainabledevelopment/blog/2018/09/who-calls-for-urgent-action-to-end-tb/

Woods, G., Lin, S., & Desmond, E. (2019). Susceptibility test methods: Mycobacteria, Nocardia, and other actinomycetes. Manual of Clinical Microbiology, (12th ed.) ASM Press.

World Health Organization (WHO). (2021). Estimated incidence of MDR/RR tuberculosis (TB) in 2019. https://publichealthmaps.org/motw-2021/2021/3/24/24-march-2021-estimated-incidence-of-mdr-rr-tuberculosis-tb-in-2019.

World Health Organization (WHO). (2023). Estimated TB Incidence Rates 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-disease-burden/1-1-tb-incidence

World Health Organization (WHO). (2021). Global tuberculosis report 2021. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021

World Health Organization (WHO). (2023). Global tuberculosis report 2023. https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequence=1

World Health Organization. (2023). Global tuberculosis report, 2023: 1.3 drug-resistant TB. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-disease-burden/1-3-drug-resistant-tb

World Health Organization. (2022). Module 4: treatment - drug-resistant tuberculosis treatment. In WHO operational handbook on tuberculosis. https://www.who.int/publications/i/item/9789240065116

World Health Organization (WHO). (2024). Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis